Climb Bio to Present New Data on CLYM116 and Budoprutug at ASN Kidney Week 2026
Climb Bio, Inc. will present preliminary Phase 2 data from the PrisMN study of budoprutug and advancements across its portfolio, including CLYM116 and budoprutug programs, at the American Society of Nephrology (ASN) Kidney Week 2026.